0001493152-23-016288.txt : 20230511 0001493152-23-016288.hdr.sgml : 20230511 20230511081019 ACCESSION NUMBER: 0001493152-23-016288 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 23908953 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000868278 false 0000868278 2023-05-11 2023-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 11, 2023

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

711 Stewart Avenue, Suite 200

Garden City, New York

   11530
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 11, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD.

 

As previously announced, the Company will conduct a conference call today, Thursday, May 11, 2023, at 11:00 a.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments.

 

The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
     
99.1   Press Release dated May 11, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

  

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Robert Morse Jr.
    Robert Morse Jr.
    Chief Financial Officer

 

Date: May 11, 2023

 

  

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

ProPhase Labs Announces Financial Results

for the Three Months Ended March 31, 2023

 

As revenue mix transitions, Company still achieves positive net income and significant adjusted EBITDA while acquiring and developing biotech, genomics and diagnostic assets with multi-billion-dollar potential

 

Company highlights key strategic initiatives to grow underlying value in 2023 and beyond

 

Company to hold a conference call Thursday, May 11, 2023, at 11:00 AM ET

 

Garden City, NY – May 11, 2023 (GLOBE NEWSWIRE) – ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2023.

 

Corporate highlights for the three months ended March 31, 2023, include the following:

 

  ● Advancing key initiatives associated with Linebacker-1 cancer compound at the world-renowned Dana Farber Cancer Institute with Harvard University professors/scientists.
     
  ● Conducting vital pre-clinical analysis of Linebacker-1 at Eurofins and Reprocell.
     
  ● Developing the BE-Smart Esophageal Cancer Test with world-renowned Key Opinion Leaders at Mayo Institute, Kansas University Medical Center (KUMC) and Baylor University.
     
  ● Continuing sample acquisition and testing of BE-Smart Test at the cutting-edge facility at Mprobe.
     
  ● Developing Nebula Genomics with Dr. George Church and Russ B. Altman, MD, PhD.
     
  ● Growing Nebula Genomics with over 100% revenue growth year-over-year.
     
  ● Growing Pharmaloz Manufacturing with almost 100% year-over-year growth.
     
  ● Implemented new $6 million stock repurchase program.

 

Financial highlights for the three months ended March 31, 2023, include the following:

 

  ● Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022.
     
  ● Net Income of $0.6 million, or $0.03 per diluted share, for the three months ended March 31, 2023, as compared to net income of $12.5 million, or $0.68 per diluted share, for the three months ended March 31, 2022.
     
  ● Adjusted EBITDA of $3.1 million for the three months ended March 31, 2023, as compared to adjusted EBITDA of $14.6 million for the three months ended March 31, 2022.
     
  ● Cash, cash equivalents and marketable equity securities of $15.6 million and working capital of $42.8 million as of March 31, 2023.

 

 

 

 

Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “I could not be more pleased with our progress to date. It is a testament to our entire management team that we generated positive net income and significant adjusted EBITDA even as our revenue mix transitions away from COVID-19 to whole genome sequencing and manufacturing and while developing cancer therapeutic and diagnostic assets each with multi-billion-dollar potential.

 

In years past, we turned around and sold the Cold-EEZE Cold Remedy brand for $50 million. We then took advantage of the opportunity in COVID-19 testing to build a world-class high complexity molecular CLIA lab in the State of New York, and generate enormous revenues, earnings and working capital. We leveraged these successes to build a first-class infrastructure and platform. We spent the past two plus years exploring hundreds of potential acquisitions during the biotech bear market. We cherry picked what we believe to be the most promising technologies and are now developing these assets with multi-billion-dollar potential.

 

We feel strongly that personalized precision medicine is the future of medicine. Despite its rapid growth over the past five years, it is still in its infancy, similar to where the internet was 20 to 25 years ago. At the heart of this research is whole genome sequencing. We are working with world-class advisors and have developed strong relationships with the global leaders in whole genome sequencing equipment and consumables. We believe that we are well situated to potentially be the low-cost provider of whole genome sequencing in the United States and globally. Our current growth rate at Nebula Genomics does not reflect the potential distribution in retail stores in late 2024 and the anticipated launch of our B2B whole genome sequencing once our lab validations are complete in the next couple of months. We intend to be the go-to leading edge genomic processing lab in North America.

 

We are also developing our Linebacker-1 cancer compound and achieving impressive pre-clinical results. We recently shared some of these results from our work with Eurofins and look forward to updating our shareholders in the near future with additional results from our pre-clinical studies at Dana Farber Cancer Institute.

 

In parallel, we are developing our BE-Smart Esophageal Cancer Test with world-class organizations. We anticipate that we will achieve CPT codes and initiate commercialization and distribution in the U.S. by early 2024. We feel that the ultimate potential for this much needed, and potentially life-saving test, is in the billions of dollars.

 

And while the U.S. is certainly a multi-billion-dollar market on its own, we believe that Nebula Genomics, Linebacker and BE-Smart all have massive global potential as well.

 

We have successfully completed the build out of our diversified CLIA lab in New York to provide state-of-the-art genomics testing as well as a full clinical laboratory services. We expect all validations for our clinical lab and genomics testing to be completed within the next couple of months. We will then leverage our existing infrastructure to launch our B2B channel for Nebula Genomics and continue to build our traditional clinical lab business.

 

Finally, our Pharmaloz Manufacturing business is operating at full capacity with significant demand to potentially support $25 million or more in revenues in 2024. We are only limited by our ability to quickly and efficiently build capacity. As more and more companies look to outsource their lozenge production, Pharmaloz will continue to pick up high margin business. We continue to have strong interest from some of the largest lozenge brands, both in the U.S. and abroad.

 

Furthermore, our infrastructure will also allow us to leverage our relationships with over 40,000 Food, Drug and Mass (FDM) retail stores in the U.S. as we develop and commercialize our Equivir broad based anti-viral as a dietary supplement and introduce our Nebula whole genome sequencing (WGS) tests in these same stores.

 

We are all looking forward to a bright future and plan to provide further updates to our loyal shareholders in the near term,” concluded Mr. Karkus.

 

 

 

 

Financial Results

 

Three Months Ended March 31, 2023 as compared to the Three Months Ended March 31, 2022.

 

For the three months ended March 31, 2023, net revenue was $19.3 million as compared to $47.5 million for the three months ended March 31, 2022. The decrease in net revenue was the result of a $30.4 decrease in net revenue from diagnostic services, partially offset by a $2.2 million increase in consumer products. The decrease in net revenue for diagnostic services was due to decreased COVID-19 testing volumes compared to the 2022 period, which saw a spike in COVID-19 testing as a result of the Omicron variant, which emerged in early 2022. Overall diagnostic testing volume decreased from 377,000 tests in the first quarter of 2022 to 120,000 tests in the first quarter of 2023, of which 69.0% and —% were reimbursed by the HRSA uninsured program, respectively. The average variable consideration received was $121.03 per adjudicated test in the first quarter of 2023 compared to $120.14 per adjudicated test in the first quarter of 2022.

 

Cost of revenues for the three months ended March 31, 2023 were $8.8 million, comprised of $5.2 million for diagnostic services and $3.6 million for consumer products. Cost of revenues for the three months ended March 31, 2022 were $18.9 million, comprised of $16.7 million for diagnostic services and $2.2 million for consumer products.

We realized a gross profit of $10.5 million for the three months ended March 31, 2023 as compared to $28.7 million for the three months ended March 31, 2022. The decrease of $18.2 million was comprised of a decrease of $18.9 million in diagnostic services, partially offset by an increase of $0.8 million in consumer products. For the three months ended March 31, 2023 and 2022, we realized an overall gross margin of 54.5% and 60.3%, respectively. Gross margin for diagnostic services was 64.0% and 62.8% in the 2023 and 2022 comparable periods, respectively. The increase in gross margin was principally due to (i) increased efficiencies in our lab processing, (ii) a decrease in sample collection costs and (iii) a decrease in cost of test materials. Gross margin for consumer products was 25.5% and 17.8% in the 2023 and 2022 comparable periods, respectively. Gross margin for consumer products have historically been influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs and timing of shipments to customers.

 

Diagnostic services costs for the three months ended March 31, 2023 were $1.2 million compared to $4.7 million for the three months ended March 31, 2022. The decrease of $3.5 million was due to decreased COVID-19 testing volumes in 2023 compared to the 2022 period, which saw a spike in COVID-19 testing as a result of the Omicron variant, which emerged in late 2021.

 

General and administration expenses for the three months ended March 31, 2023 were $8.3 million as compared to $7.8 million for the three months ended March 31, 2022. The increase of $0.5 million in general and administration expenses was principally related to an increase in personnel expenses and professional fees associated with our diagnostic services business.

 

Research and development costs for the three months ended March 31, 2023 were $144,000 as compared to $35,000 for the three months ended March 31, 2022. The increase in research and development costs for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 was principally due to increased activities at ProPhase Biopharma, Inc. (PBIO). These activities include product research and field testing.

 

Our aggregate cash and cash equivalents as of March 31, 2023 were $9.6 million as compared to $9.1 million at December 31, 2022. Our working capital was 42.8 million and $44.8 million as of March 31, 2023 and December 31, 2022, respectively. The increase of $0.5 million in our cash and cash equivalents for the three months ended March 31, 2023 was principally due to the proceeds from the sale of marketable debt securities of $1.3 million, proceeds from the issuance of notes payable of $7.6 million, and $0.5 million cash provided by operating activities, offset by (i) our acquisition of the world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening test and related intellectual property assets from Stella Diagnostics, Inc. for approximately $4.5 million, comprised of approximately $3.5 million in cash and $1 million in common stock, (ii) the repurchase of common shares for payment of statutory taxes due on cashless exercise of options of $5.4 million, and (iii) the repurchase of common shares for $0.5 million and (iii) capital expenditures of $0.5 million.

 

 

 

 

Conference Call and Webcast Details

 

Management will host a conference call at 11:00 AM ET, Thursday, May 11, 2023, to provide an update on corporate developments and review financial results. Following management’s formal remarks, there will be a question-and-answer session.

 

Participants can register for the conference call by navigating to:

https://dpregister.com/sreg/10178710/f95cce1458

 

Please note that registered participants will receive their dial-in number upon registration and may dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international). All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into ProPhase Lab’s call.

 

The conference call will be broadcast live and available for replay at

https://event.choruscall.com/mediaframe/webcast.html?webcastid=bQyqnuoI and via the investor relations section of the Company’s website at www.ProPhaseLabs.com.

 

A webcast replay of the call will be available approximately two hours after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 9261373.

 

About ProPhase Labs

 

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscores our multi-billion dollar potential.

 

Forward Looking Statements

 

Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our plans to grow our subsidiaries and build a multi-billion dollar company, our expectations regarding the future revenue growth potential of each of our subsidiaries, our plans to sell our products in food, drug and mass (FDM) stores, our expected timeline for commercializing our BE-Smart Test and its market potential, and the market potential of Equivir (dietary supplement) and Linebacker-1, , as well as our plans to become the low-cost provider of and leader in whole genomic sequencing and to expand our New York lab to include both traditional clinical testing and genomic sequencing. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

 

For more information, visit www.ProPhaseLabs.com.

 

ProPhase Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.

267-880-1111

investorrelations@prophaselabs.com

 

ProPhase Retail Investor Relations Contact:

Renmark Financial Communications

John Boidman

514-939-3989

Jboidman@renmarkfinancial.com

 

Source: ProPhase Labs, Inc.

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

   March 31, 2023   December 31, 2022 
    (Unaudited)       
ASSETS          
Current assets          
Cash and cash equivalents  $9,613   $9,109 
Marketable debt securities, available for sale   5,946    8,328 
Accounts receivable, net   37,836    37,054 
Inventory, net   4,311    3,976 
Prepaid expenses and other current assets   3,573    2,366 
Total current assets   61,279    60,833 
           
Property, plant and equipment, net   8,891    7,288 
Prepaid expenses, net of current portion   121    121 
Operating lease right-of-use asset, net   3,974    4,059 
Intangible assets, net   14,524    8,475 
Goodwill   5,231    5,709 
Deferred tax asset   191    — 
Other assets   1,163    1,163 
TOTAL ASSETS  $95,374   $87,648 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $4,866   $5,905 
Accrued diagnostic services   353    1,009 
Accrued advertising and other allowances   151    99 
Operating lease liabilities   298    301 
Deferred revenue   2,841    2,499 
Income tax payable   3,849    4,190 
Other current liabilities   6,109    2,072 
Total current liabilities   18,467    16,075 
           
Non-current liabilities:          
Deferred revenue, net of current portion   1,160    1,059 
Deferred tax liability, net   —    224 
Unsecured promissory notes, net of discount of $376 and $0   7,224    — 
Unsecured convertible promissory notes, net   2,400    2,400 
Operating lease liabilities, net of current portion   4,182    4,259 
Due to sellers (see Note 3)   2,000    — 
Total non-current liabilities   16,966    7,942 
Total liabilities   35,433    24,017 
           
COMMITMENTS AND CONTINGENCIES          
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding   —    — 
Common stock authorized 50,000,000, $0.0005 par value, 16,851,041 and 16,210,776 shares outstanding, respectively   17    16 
Additional paid-in capital   111,482    109,138 
Retained earnings   12,303    11,753 
Treasury stock, at cost, 18,934,955 and 18,126,970 shares, respectively   (63,953)   (58,033)
Accumulated other comprehensive loss   92    757 
Total stockholders’ equity   59,941    63,631 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $95,374   $87,648 

 

See accompanying notes to these condensed consolidated financial statements

 

 

 

 

PROPHASE LABS, INC & SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

(unaudited)

 

   For the three months ended 
   March 31, 2023   March 31, 2022 
Revenues, net  $19,303   $47,531 
Cost of revenues   8,783    18,854 
Gross profit   10,520    28,677 
           
Operating expenses:          
Diagnostic expenses   1,203    4,672 
General and administration   8,298    7,824 
Research and development   144    35 
Total operating expenses   9,645    12,531 
Income from operations   875    16,146 
           
Interest income, net   11    73 
Interest expense   (215)   (233)
Other income (loss)   (107)   (76)
Income from operations before income taxes   564    15,910 
Income tax expense (benefit)   14    (3,416)
Income from operations after income taxes   550    12,494 
Net income  $550   $12,494 
           
Other comprehensive (loss) income:          
Unrealized loss on marketable debt securities   (665)   37 
Total comprehensive (loss) income  $(115)  $12,531 
           
Earnings per share:          
Basic  $0.03   $0.81 
Diluted  $0.03   $0.68 
           
Weighted average common shares outstanding:          
Basic   16,748    15,486 
Diluted   18,061    18,740 

 

See accompanying notes to these condensed consolidated financial statements

 

 

 

 

PROPHASE LABS, INC & SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

   For the three months ended 
   March 31, 2023   March 31, 2022 
Cash flows from operating activities          
Net income  $550   $12,494 
Adjustments to reconcile net income to net cash provided by operating activities:          
Realized loss on marketable debt securities   107    179 
Depreciation and amortization   1,292    1,249 
Accretion of debt discount   20    1 
Amortization on operating lease right-of-use assets   85    83 
Gain on sale of assets   —    (23)
Stock-based compensation expense   947    482 
Change in fair value of investment securities   —    76 
Accounts receivable allowances   (147)   (924)
Inventory valuation reserve   —    25 
Bad debt expenses   230    — 
Changes in operating assets and liabilities:          
Accounts receivable   (864)   1,938 
Inventory   (335)   (105)
Prepaid expenses and other current assets   (2,107)   (126)
Deferred tax asset   (96)   — 
Other assets   —    360 
Accounts payable and accrued expenses   (2,661)   1,178 
Accrued diagnostic services   (656)   (878)
Accrued advertising and other allowances   52    — 
Deferred revenue   443    165 
Deferred tax liability   —    443 
Operating lease liabilities   (80)   (73)
Income tax payable   (341)   2,973 
Other current liabilities   4,037    770 
Net cash provided by operating activities   476    20,287 
           
Cash flows from investing activities          
Business acquisitions, escrow received   478    — 
Asset acquisition, net of cash acquired   (2,904)   — 
Purchase of marketable securities   —    (206)
Proceeds from sale of marketable debt securities   1,291    5,300 
Proceeds from dispositions of property and other assets, net   —    85 
Capital expenditures   (517)   (1,095)
Net cash (used in) provided by investing activities   (1,652)   4,084 
           
Cash flows from financing activities          
Proceeds from issuance of secured note payable   7,600    — 
Repurchase of common stock for payment of statutory taxes due on cashless exercise of stock option   (5,379)   — 
Repurchases of common shares   (541)   (1,150)
Repayment of note payable   —    (1,426)
Payment of dividends   —    (4,646)
Net cash provided by (used in) financing activities   1,680    (7,222)
           
Increase in cash, cash equivalents and restricted cash   504    17,149 
Cash and cash equivalents, at the beginning of the period   9,109    8,658 
Cash and cash equivalents, at the end of the period  $9,613   $25,807 
           
Supplemental disclosures:          
Cash paid for income taxes  $1,500   $— 
Interest payment on the promissory notes  $203   $241 
           
Supplemental disclosure of non-cash investing and financing activities:          
Financed capital expenditures  $1,623   $— 
Common stock issued in Asset Acquisition  $1,000   $— 
Issuance of common shares for debt conversion  $—   $600 
Net unrealized loss, investments in marketable debt securities  $—   $37 

 

See accompanying notes to these condensed consolidated financial statements

 

 

 

 

Non-GAAP Financial Measure and Reconciliation

(unaudited)

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measures we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from the non-GAAP financial measures.

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our operating results primarily because they exclude amounts that are not considered part of ongoing operating results when planning and forecasting and when assessing the performance of the organization. In addition, we believe that non-GAAP financial information is used by analysts and others in the investment community to analyze our historical results and in providing estimates of future performance and that failure to report these non-GAAP measures could result in confusion among analysts and others and create a misplaced perception that our results have underperformed or exceeded expectations.

 

The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

   For the three months ended 
   March 31, 2023   March 31, 2022 
GAAP net income (1)  $550   $12,494 
Interest, net   204    160 
Income tax expense   14    — 
Depreciation and amortization   1,292    1,250 
EBITDA   2,060    13,904 
Share-based compensation expense   947    482 
Non-cash rent expense (2)   6    10 
Bad debt expense   74    250 
Adjusted EBITDA  $3,087   $14,646 

 

  (1) We believe that net income is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.
  (2) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 prph-20230511.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prph-20230511_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 prph-20230511_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2023
Entity File Number 000-21617
Entity Registrant Name PROPHASE LABS, INC.
Entity Central Index Key 0000868278
Entity Tax Identification Number 23-2577138
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 711 Stewart Avenue
Entity Address, Address Line Two Suite 200
Entity Address, Address Line Three G
Entity Address, City or Town arden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (215)
Local Phone Number 345-0919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0005
Trading Symbol PRPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000868278 2023-05-11 2023-05-11 iso4217:USD shares iso4217:USD shares 0000868278 false 8-K 2023-05-11 PROPHASE LABS, INC. DE 000-21617 23-2577138 711 Stewart Avenue Suite 200 G arden City NY 11530 (215) 345-0919 false false false false Common Stock, par value $0.0005 PRPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prph-20230511.xsd prph-20230511_lab.xml prph-20230511_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prph-20230511_lab.xml" ] }, "presentationLink": { "local": [ "prph-20230511_pre.xml" ] }, "schema": { "local": [ "prph-20230511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20230511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-11to2023-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-05-11to2023-05-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-016288-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-016288-xbrl.zip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